Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Immunomodulation of Tumor Vessels: It Takes Two to Tango.

Johansson-Percival A, He B, Ganss R.

Trends Immunol. 2018 Oct;39(10):801-814. doi: 10.1016/j.it.2018.08.001. Epub 2018 Aug 25. Review.

PMID:
30153971
2.

Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules.

He B, Jabouille A, Steri V, Johansson-Percival A, Michael IP, Kotamraju VR, Junckerstorff R, Nowak AK, Hamzah J, Lee G, Bergers G, Ganss R.

J Pathol. 2018 Jun;245(2):209-221. doi: 10.1002/path.5080. Epub 2018 Apr 20.

3.

Ultrahigh-Resolution Optical Coherence Elastography Images Cellular-Scale Stiffness of Mouse Aorta.

Wijesinghe P, Johansen NJ, Curatolo A, Sampson DD, Ganss R, Kennedy BF.

Biophys J. 2017 Dec 5;113(11):2540-2551. doi: 10.1016/j.bpj.2017.09.022.

4.

Ultrahigh-resolution optical coherence elastography through a micro-endoscope: towards in vivo imaging of cellular-scale mechanics.

Fang Q, Curatolo A, Wijesinghe P, Yeow YL, Hamzah J, Noble PB, Karnowski K, Sampson DD, Ganss R, Kim JK, Lee WM, Kennedy BF.

Biomed Opt Express. 2017 Oct 20;8(11):5127-5138. doi: 10.1364/BOE.8.005127. eCollection 2017 Nov 1.

5.

De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors.

Johansson-Percival A, He B, Li ZJ, Kjellén A, Russell K, Li J, Larma I, Ganss R.

Nat Immunol. 2017 Nov;18(11):1207-1217. doi: 10.1038/ni.3836. Epub 2017 Sep 11.

PMID:
28892469
6.

Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.

Zhao Y, Ting KK, Li J, Cogger VC, Chen J, Johansson-Percival A, Ngiow SF, Holst J, Grau G, Goel S, Muller T, Dejana E, McCaughan G, Smyth MJ, Ganss R, Vadas MA, Gamble JR.

Cancer Res. 2017 Aug 15;77(16):4434-4447. doi: 10.1158/0008-5472.CAN-16-3129. Epub 2017 Jun 27. Erratum in: Cancer Res. 2018 Oct 1;78(19):5718.

7.

Tumour vessel normalization and immune checkpoint blockade: a new synergism.

Ganss R.

Immunol Cell Biol. 2017 Jul;95(6):497-498. doi: 10.1038/icb.2017.30. Epub 2017 May 23. No abstract available.

PMID:
28534503
8.

Maternal Metabolism and Vascular Adaptation in Pregnancy: The PPAR Link.

Ganss R.

Trends Endocrinol Metab. 2017 Jan;28(1):73-84. doi: 10.1016/j.tem.2016.09.004. Epub 2016 Oct 24. Review.

9.

Levels of Hair Ethyl Glucuronide in Patients with Decreased Kidney Function: Possibility of Misclassification of Social Drinkers.

Fosen JT, Morini L, Sempio C, Ganss R, Mørland J, Høiseth G.

Alcohol Clin Exp Res. 2016 Mar;40(3):451-6. doi: 10.1111/acer.12970. Epub 2016 Feb 8.

PMID:
26853225
10.

Intratumoral LIGHT Restores Pericyte Contractile Properties and Vessel Integrity.

Johansson-Percival A, Li ZJ, Lakhiani DD, He B, Wang X, Hamzah J, Ganss R.

Cell Rep. 2015 Dec 29;13(12):2687-98. doi: 10.1016/j.celrep.2015.12.004. Epub 2015 Dec 17.

11.

Kupffer cell-monocyte communication is essential for initiating murine liver progenitor cell-mediated liver regeneration.

Elsegood CL, Chan CW, Degli-Esposti MA, Wikstrom ME, Domenichini A, Lazarus K, van Rooijen N, Ganss R, Olynyk JK, Yeoh GC.

Hepatology. 2015 Oct;62(4):1272-84. doi: 10.1002/hep.27977. Epub 2015 Jul 31.

PMID:
26173184
12.

Keeping the Balance Right: Regulator of G Protein Signaling 5 in Vascular Physiology and Pathology.

Ganss R.

Prog Mol Biol Transl Sci. 2015;133:93-121. doi: 10.1016/bs.pmbts.2015.02.003. Epub 2015 Apr 1. Review.

PMID:
26123304
13.

More than a scaffold: Stromal modulation of tumor immunity.

Johansson A, Hamzah J, Ganss R.

Biochim Biophys Acta. 2016 Jan;1865(1):3-13. doi: 10.1016/j.bbcan.2015.06.001. Epub 2015 Jun 10. Review.

PMID:
26071879
14.

Regulator of G protein signaling 5 is a determinant of gestational hypertension and preeclampsia.

Holobotovskyy V, Chong YS, Burchell J, He B, Phillips M, Leader L, Murphy TV, Sandow SL, McKitrick DJ, Charles AK, Tare M, Arnolda LF, Ganss R.

Sci Transl Med. 2015 Jun 3;7(290):290ra88. doi: 10.1126/scitranslmed.aaa5038.

15.

License for destruction: tumor-specific cytokine targeting.

Johansson A, Hamzah J, Ganss R.

Trends Mol Med. 2014 Jan;20(1):16-24. doi: 10.1016/j.molmed.2013.10.002. Epub 2013 Oct 26. Review.

16.

Regulator of G-protein signaling 5 controls blood pressure homeostasis and vessel wall remodeling.

Holobotovskyy V, Manzur M, Tare M, Burchell J, Bolitho E, Viola H, Hool LC, Arnolda LF, McKitrick DJ, Ganss R.

Circ Res. 2013 Mar 1;112(5):781-91. doi: 10.1161/CIRCRESAHA.111.300142. Epub 2013 Jan 9.

17.

Intratumoral TNFα improves immunotherapy.

Johansson A, Hamzah J, Ganss R.

Oncoimmunology. 2012 Nov 1;1(8):1395-1397.

18.

Matrigel basement membrane matrix influences expression of microRNAs in cancer cell lines.

Price KJ, Tsykin A, Giles KM, Sladic RT, Epis MR, Ganss R, Goodall GJ, Leedman PJ.

Biochem Biophys Res Commun. 2012 Oct 19;427(2):343-8. doi: 10.1016/j.bbrc.2012.09.059. Epub 2012 Sep 18.

PMID:
23000157
19.

Higher levels of hair ethyl glucuronide in patients with decreased kidney function.

Høiseth G, Morini L, Ganss R, Nordal K, Mørland J.

Alcohol Clin Exp Res. 2013 Jan;37 Suppl 1:E14-6. doi: 10.1111/j.1530-0277.2012.01882.x. Epub 2012 Jun 14.

PMID:
22698262
20.

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

Johansson A, Hamzah J, Payne CJ, Ganss R.

Proc Natl Acad Sci U S A. 2012 May 15;109(20):7841-6. doi: 10.1073/pnas.1118296109. Epub 2012 Apr 30.

21.

Remodeling of tumor stroma and response to therapy.

Johansson A, Ganss R.

Cancers (Basel). 2012 Mar 27;4(2):340-53. doi: 10.3390/cancers4020340.

22.

Invading macrophages play a major role in the liver progenitor cell response to chronic liver injury.

Viebahn CS, Benseler V, Holz LE, Elsegood CL, Vo M, Bertolino P, Ganss R, Yeoh GC.

J Hepatol. 2010 Sep;53(3):500-7. doi: 10.1016/j.jhep.2010.04.010. Epub 2010 May 26.

PMID:
20561705
23.

Secreted frizzled-related protein 4: an angiogenesis inhibitor.

Muley A, Majumder S, Kolluru GK, Parkinson S, Viola H, Hool L, Arfuso F, Ganss R, Dharmarajan A, Chatterjee S.

Am J Pathol. 2010 Mar;176(3):1505-16. doi: 10.2353/ajpath.2010.090465. Epub 2010 Jan 7.

24.

Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.

Hamzah J, Altin JG, Herringson T, Parish CR, Hämmerling GJ, O'Donoghue H, Ganss R.

J Immunol. 2009 Jul 15;183(2):1091-8. doi: 10.4049/jimmunol.0900736. Epub 2009 Jun 26.

25.

Regulator of G protein signaling 5: a new player in vascular remodeling.

Manzur M, Ganss R.

Trends Cardiovasc Med. 2009 Jan;19(1):26-30. doi: 10.1016/j.tcm.2009.04.002. Review.

PMID:
19467451
26.

Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma.

Stahl S, Sacher T, Bechtold A, Protzer U, Ganss R, Hämmerling GJ, Arnold B, Garbi N.

Immunol Lett. 2009 Mar 24;123(1):31-7. doi: 10.1016/j.imlet.2009.01.011. Epub 2009 Feb 25.

PMID:
19428549
27.

Modulation of g protein signaling normalizes tumor vessels.

Manzur M, Hamzah J, Ganss R.

Cancer Res. 2009 Jan 15;69(2):396-9. doi: 10.1158/0008-5472.CAN-08-2842. Review.

28.

Modulation of the "blood-tumor" barrier improves immunotherapy.

Manzur M, Hamzah J, Ganss R.

Cell Cycle. 2008 Aug 15;7(16):2452-5. Epub 2008 Aug 17.

PMID:
18719382
29.

Vascular normalization in Rgs5-deficient tumours promotes immune destruction.

Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, Rabie T, Kaden S, Gröne HJ, Hämmerling GJ, Arnold B, Ganss R.

Nature. 2008 May 15;453(7193):410-4. doi: 10.1038/nature06868. Epub 2008 Apr 16.

PMID:
18418378
30.

Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice.

Hamzah J, Nelson D, Moldenhauer G, Arnold B, Hämmerling GJ, Ganss R.

J Clin Invest. 2008 May;118(5):1691-9. doi: 10.1172/JCI33201.

31.

Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM.

Du R, Petritsch C, Lu K, Liu P, Haller A, Ganss R, Song H, Vandenberg S, Bergers G.

Neuro Oncol. 2008 Jun;10(3):254-64. doi: 10.1215/15228517-2008-001. Epub 2008 Mar 21.

32.

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.

Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegué E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G.

Cancer Cell. 2008 Mar;13(3):206-20. doi: 10.1016/j.ccr.2008.01.034.

33.

Kidney biopsies taken before and after oral sodium phosphate bowel cleansing.

Aasebø W, Scott H, Ganss R.

Nephrol Dial Transplant. 2007 Mar;22(3):920-2. Epub 2006 Nov 30. No abstract available.

PMID:
17138571
34.
36.

CD8+ regulatory T cells generated by neonatal recognition of peripheral self-antigen.

Reibke R, Garbi N, Ganss R, Hämmerling GJ, Arnold B, Oelert T.

Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15142-7. Epub 2006 Sep 28.

37.

Tumor growth or regression: powered by inflammation.

Nelson D, Ganss R.

J Leukoc Biol. 2006 Oct;80(4):685-90. Epub 2006 Jul 24. Review.

PMID:
16864602
38.

Vascular integration of endothelial progenitors during multistep tumor progression.

Hämmerling GJ, Ganss R.

Cell Cycle. 2006 Mar;5(5):509-11. Epub 2006 Mar 1.

PMID:
16552180
39.

Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis.

Schledzewski K, Falkowski M, Moldenhauer G, Metharom P, Kzhyshkowska J, Ganss R, Demory A, Falkowska-Hansen B, Kurzen H, Ugurel S, Geginat G, Arnold B, Goerdt S.

J Pathol. 2006 May;209(1):67-77.

PMID:
16482496
40.

Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma.

Ryschich E, Lizdenis P, Ittrich C, Benner A, Stahl S, Hamann A, Schmidt J, Knolle P, Arnold B, Hämmerling GJ, Ganss R.

Cancer Res. 2006 Jan 1;66(1):198-211.

41.

Chemokines direct endothelial progenitors into tumor neovessels.

Spring H, Schüler T, Arnold B, Hämmerling GJ, Ganss R.

Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18111-6. Epub 2005 Dec 2.

42.

Stimulation of autoimmunity by toll-like receptor ligands.

Limmer A, Ganss R, Garbi N, Arnold B, Hämmerling GJ.

Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv15-7. Review. No abstract available.

43.

Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization.

Berger M, Bergers G, Arnold B, Hämmerling GJ, Ganss R.

Blood. 2005 Feb 1;105(3):1094-101. Epub 2004 Sep 30.

44.

Mini-review: overcoming tumor-intrinsic resistance to immune effector function.

Ganss R, Arnold B, Hämmerling GJ.

Eur J Immunol. 2004 Oct;34(10):2635-41. Review.

45.

CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction.

Garbi N, Arnold B, Gordon S, Hämmerling GJ, Ganss R.

J Immunol. 2004 May 15;172(10):5861-9.

46.

Heterogeneity of non-insulin-dependent diabetes expressed as variability in insulin sensitivity, beta-cell function and cardiovascular risk profile.

Birkeland KI, Kilhovd B, Thorsby P, Torjesen PA, Ganss R, Vaaler S, Hanssen KF.

Diabet Med. 2003 Jan;20(1):37-45.

PMID:
12519318
47.

Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.

Ganss R, Ryschich E, Klar E, Arnold B, Hämmerling GJ.

Cancer Res. 2002 Mar 1;62(5):1462-70.

48.

Transformation of the microvascular system during multistage tumorigenesis.

Ryschich E, Schmidt J, Hämmerling GJ, Klar E, Ganss R.

Int J Cancer. 2002 Feb 20;97(6):719-25.

49.

NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.

Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hämmerling GJ.

J Immunol. 2001 Nov 1;167(9):5247-53.

50.

Autoaggression and tumor rejection: it takes more than self-specific T-cell activation.

Ganss R, Limmer A, Sacher T, Arnold B, Hämmerling GJ.

Immunol Rev. 1999 Jun;169:263-72. Review.

PMID:
10450523

Supplemental Content

Support Center